Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1995 1
1997 5
1998 2
1999 2
2000 2
2001 1
2002 2
2004 2
2005 7
2006 15
2007 2
2008 4
2009 4
2010 4
2012 5
2013 6
2014 1
2015 4
2016 4
2017 4
2018 10
2019 6
2020 4
2021 4
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Psychedelic Fauna for Psychonaut Hunters: A Mini-Review.
Orsolini L, Ciccarese M, Papanti D, De Berardis D, Guirguis A, Corkery JM, Schifano F. Orsolini L, et al. Among authors: ciccarese m. Front Psychiatry. 2018 May 22;9:153. doi: 10.3389/fpsyt.2018.00153. eCollection 2018. Front Psychiatry. 2018. PMID: 29910745 Free PMC article. Review.
An update on first line therapies for metastatic breast cancer.
Fedele P, Ciccarese M, Surico G, Cinieri S. Fedele P, et al. Among authors: ciccarese m. Expert Opin Pharmacother. 2018 Feb;19(3):243-252. doi: 10.1080/14656566.2018.1425680. Epub 2018 Jan 16. Expert Opin Pharmacother. 2018. PMID: 29336185 Review.
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M, Torre SD, Villa F, Giordano M, Verusio C, Nicolini M, Gambaro AR, Zanlorenzi L, Biraghi E, Casini E, Legramandi L, Rulli E. Cazzaniga ME, et al. Among authors: ciccarese m. Int J Breast Cancer. 2017;2017:1683060. doi: 10.1155/2017/1683060. Epub 2017 Dec 3. Int J Breast Cancer. 2017. PMID: 29333297 Free PMC article. Review.
Self-monitoring versus standard monitoring of oral anticoagulation.
Ferretti G, Giannarelli D, Carlini P, Felici A, Ciccarese M, Mandalà M, Cognetti F. Ferretti G, et al. Among authors: ciccarese m. Thromb Res. 2007;119(3):389-90. doi: 10.1016/j.thromres.2006.08.007. Epub 2006 Oct 4. Thromb Res. 2007. PMID: 17023029 Review. No abstract available.
Alfa-epoietin and anaemia in gynaecological cancer.
Di Cocco B, Salesi N, Fabi A, Nardoni C, Ferretti G, Bossone G, Ciccarese M, Savarese A, Vecchione A, Cognetti F. Di Cocco B, et al. Among authors: ciccarese m. Anticancer Res. 2004 Mar-Apr;24(2C):1287-92. Anticancer Res. 2004. PMID: 15154662 Free article. Review.
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
Trevisan B, Pepe FF, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V, Cazzaniga ME; VICTOR Study Group. Trevisan B, et al. Among authors: ciccarese m. Sci Rep. 2023 Jul 28;13(1):12255. doi: 10.1038/s41598-023-39386-x. Sci Rep. 2023. PMID: 37507480 Free PMC article.
97 results